## Sheldon W Tobe

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1364280/publications.pdf

Version: 2024-02-01

137 papers

7,341 citations

43 h-index 82 g-index

142 all docs 142 docs citations

times ranked

142

8243 citing authors

#	Article	IF	CITATIONS
1	KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic KidneyÂDisease. Kidney International, 2021, 99, S1-S87.	2.6	497
2	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
3	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
4	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	6.3	408
5	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
6	The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health, The, 2017, 2, e108-e120.	4.7	315
7	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
8	Measurement of Blood Pressure in the Office. Hypertension, 2010, 55, 195-200.	1.3	241
9	Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ: British Medical Journal, 2011, 342, d286-d286.	2.4	240
10	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
11	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
12	Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 2021, 99, 559-569.	2.6	169
13	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
14	Supramaximal Dose of Candesartan in Proteinuric Renal Disease. Journal of the American Society of Nephrology: JASN, 2009, 20, 893-900.	3.0	156
15	Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk. Circulation, 2011, 123, 1098-1107.	1.6	135
16	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
17	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
18	Sexâ€Specific Associations Between Alcohol Consumption and Incidence of Hypertension: A Systematic Review and Metaâ€Analysis of Cohort Studies. Journal of the American Heart Association, 2018, 7, .	1.6	111

#	Article	IF	CITATIONS
19	A New Algorithm for the Diagnosis of Hypertension inÂCanada. Canadian Journal of Cardiology, 2015, 31, 620-630.	0.8	88
20	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 $\hat{a} \in \text{``therapy. Canadian Journal of Cardiology, 2007, 23, 539-550.}$	0.8	87
21	Central blood volume in cirrhosis: Measurement with radionuclide angiography. Hepatology, 1994, 19, 312-321.	3.6	83
22	Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga: Results From the Harmony Randomized Controlled Trial. American Journal of Hypertension, 2014, 27, 122-129.	1.0	81
23	Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial. Cmaj, 2006, 174, 1267-1271.	0.9	75
24	Estimated Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk. Annals of Internal Medicine, 2011, 154, 310.	2.0	74
25	A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. Journal of Critical Care, 2003, 18, 121-129.	1.0	69
26	Contemporary Use of $\hat{l}^2$ -Blockers: Clinical Relevance of Subclassification. Canadian Journal of Cardiology, 2014, 30, S9-S15.	0.8	69
27	The Impact of Job Strain and Marital Cohesion on Ambulatory Blood Pressure During 1 Year: The Double Exposure Study. American Journal of Hypertension, 2007, 20, 148-153.	1.0	62
28	Unpacking the Black Box: A Formative Research Approach to the Development of Theory-Driven, Evidence-Based, and Culturally Safe Text Messages in Mobile Health Interventions. JMIR MHealth and UHealth, 2016, 4, e10.	1.8	62
29	Continuous veno–venous haemodialysis with a novel bicarbonate dialysis solution: prospective cross-over comparison with a lactate buffered solution. Nephrology Dialysis Transplantation, 1999, 14, 2387-2391.	0.4	61
30	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2005, 21, 645-56.	0.8	61
31	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 $\hat{a} \in \hat{b}$ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.	0.8	60
32	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 2018, 20, 1369-1376.	2.2	60
33	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1027-1036.	2.6	60
34	Acute change in glomerular filtration rate withÂinhibition of the renin-angiotensin systemÂdoes notÂpredict subsequent renal andÂcardiovascularÂoutcomes. Kidney International, 2017, 91, 683-690.	2.6	59
35	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2006, 22, 573-581.	0.8	56
36	Healthy Food Procurement Policies and Their Impact. International Journal of Environmental Research and Public Health, $2014,11,2608-2627.$	1.2	56

#	Article	IF	CITATIONS
37	Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries. Cardiology Clinics, 2017, 35, 99-115.	0.9	56
38	Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. Cmaj, 2011, 183, E1135-E1150.	0.9	52
39	î <sup>2</sup> -Blockers in Hypertension: Studies and Meta-analyses OverÂthe Years. Canadian Journal of Cardiology, 2014, 30, S16-S22.	0.8	51
40	Relationship of Albuminuria and Renal Artery Stent Outcomes. Hypertension, 2016, 68, 1145-1152.	1.3	50
41	A Framework for Discussion on How to Improve Prevention, Management, and Control of Hypertension in Canada. Canadian Journal of Cardiology, 2012, 28, 262-269.	0.8	49
42	The conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Journal of Hypertension, 2012, 30, 1937-1941.	0.3	45
43	A Framework for the Study of Complex mHealth Interventions in Diverse Cultural Settings. JMIR MHealth and UHealth, 2017, 5, e47.	1.8	45
44	The 2001 Canadian recommendations for the management of hypertension: Part two-Therapy. Canadian Journal of Cardiology, 2002, 18, 625-41.	0.8	44
45	Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 1270-1281.	2.0	41
46	Inhibiting the Progression of Arterial Calcification with Vitamin K in HemoDialysis Patients (iPACK-HD) Trial: Rationale and Study Design for a Randomized Trial of Vitamin K in Patients with End Stage Kidney Disease. Canadian Journal of Kidney Health and Disease, 2015, 2, 53.	0.6	40
47	Impact of Job and Marital Strain on Ambulatory Blood PressureResults from the Double Exposure Study. American Journal of Hypertension, 2005, 18, 1046-1051.	1.0	39
48	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
49	Marital support, spousal contact and the course of mild hypertension. Journal of Psychosomatic Research, 2003, 55, 229-233.	1.2	37
50	Hypertension in people with type 2 diabetes: Update on pharmacologic management. Canadian Family Physician, 2011, 57, 997-1002, e347-53.	0.1	37
51	Refractory ascites: Modulation of atrial natriuretic factor unresponsiveness by mannitol. Hepatology, 1992, 16, 42-48.	3.6	36
52	Marital cohesion and ambulatory blood pressure in early hypertension. American Journal of Hypertension, 1999, 12, 227-230.	1.0	35
53	I-RREACH: an engagement and assessment tool for improving implementation readiness of researchers, organizations and communities in complex interventions. Implementation Science, 2015, 10, 64.	2.5	35
54	Hypertension in Canada: Past, Present, and Future. Annals of Global Health, 2018, 82, 288.	0.8	32

#	Article	IF	Citations
55	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. American Journal of Kidney Diseases, 2014, 63, 869-887.	2.1	31
56	Diagnosing hypertension in Indigenous Canadians ( <scp>DREAM</scp> â€ <scp>GLOBAL</scp> ): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. Journal of Clinical Hypertension, 2019, 21, 29-36.	1.0	29
57	Baseline characteristics and enrichment results from the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2018, 20, 1829-1835.	2.2	28
58	Combining Other Antihypertensive Drugs With $\hat{l}^2$ -Blockers in Hypertension: A Focus on Safety and Tolerability. Canadian Journal of Cardiology, 2014, 30, S42-S46.	0.8	27
59	Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trial. Cmaj, 2018, 190, E1273-E1280.	0.9	27
60	Hypertension Canada's 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension. Canadian Journal of Cardiology, 2020, 36, 625-634.	0.8	27
61	Renal Athersosclerotic reVascularization Evaluation (RAVE Study): Study protocol of a randomized trial [NCT00127738]. BMC Nephrology, 2007, 8, 4.	0.8	25
62	The 2001 Canadian recommendations for the management of hypertension: Part one-Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Canadian Journal of Cardiology, 2002, 18, 604-24.	0.8	25
63	Systematic Review of Hypertension and Diabetes Burden, Risk Factors, and Interventions for Prevention and Control in Malawi: The NCD BRITE Consortium. Global Heart, 2019, 14, 109.	0.9	23
64	Analysis of the Implementation, User Perspectives, and Feedback From a Mobile Health Intervention for Individuals Living With Hypertension (DREAM-GLOBAL): Mixed Methods Study. JMIR MHealth and UHealth, 2019, 7, e12639.	1.8	23
65	The Canadian Hypertension Education Program – a unique Canadian knowledge translation program. Canadian Journal of Cardiology, 2007, 23, 551-555.	0.8	20
66	Wise Practices for Cultural Safety in Electronic Health Research and Clinical Trials With Indigenous People: Secondary Analysis of a Randomized Clinical Trial. Journal of Medical Internet Research, 2019, 21, e14203.	2.1	20
67	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. Hepatology, 1993, 18, 519-528.	3.6	19
68	Renal Denervation Therapy for the Treatment of Resistant Hypertension: A Position Statement by the Canadian Hypertension Education Program. Canadian Journal of Cardiology, 2014, 30, 16-21.	0.8	19
69	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update. Cmaj, 2014, 186, 1299-1305.	0.9	19
70	The Effect of Alcohol and Gender on Ambulatory Blood Pressure: Results From the Baseline Double Exposure Study. American Journal of Hypertension, 2006, 19, 136-139.	1.0	17
71	Diabetes risk evaluation and microalbuminuria (DREAM) studies: ten years of participatory research with a First Nation's home and community model for type 2 diabetes care in Northern Saskatchewan. International Journal of Circumpolar Health, 2008, 67, 190-202.	0.5	17
72	Preventing Cardiovascular and Renal Disease in Canada's Aboriginal Populations. Canadian Journal of Cardiology, 2015, 31, 1124-1129.	0.8	17

#	Article	IF	CITATIONS
73	Atherosclerotic renovascular disease. Canadian Journal of Cardiology, 2006, 22, 623-628.	0.8	15
74	Bridging the Gap: Innovative Knowledge Translation and the Canadian Hypertension Education Program. Canadian Journal of Cardiology, 2012, 28, 258-261.	0.8	15
75	Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. Cmaj, 2013, 185, 963-967.	0.9	15
76	The Effectiveness of Text Messaging for Detection and Management of Hypertension in Indigenous People in Canada: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e244.	0.5	15
77	IMPPACT: Investigation of Medical Professionals and Patients Achieving Control Together. Canadian Journal of Cardiology, 2008, 24, 205-208.	0.8	13
78	Hypertension Analysis of stress Reduction using Mindfulness meditatiON and Yoga (The HARMONY) Tj ETQq0 0	0 rgBT /C	verlock 10 Tf
79	The Role of Desmopressin in the Management of Severe, Hypovolemic Hyponatremia: A Single-Center, Comparative Analysis. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811876105.	0.6	13
80	The Global Alliance for Chronic Diseases Supports 15 Major Studies in Hypertension Prevention and Control in Low―and Middleâ€Income Countries. Journal of Clinical Hypertension, 2016, 18, 600-605.	1.0	12
81	Central blood volume in cirrhosis: Measurement with radionuclide angiography. Hepatology, 1994, 19, 312-321.	3.6	12
82	What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?. Current Hypertension Reports, 2001, 3, 422-428.	1.5	11
83	Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI) Trial. Journal of Clinical Hypertension, 2007, 9, 120-127.	1.0	11
84	The impact of endothelin-1 genetic analysis and job strain on ambulatory blood pressure. Journal of Psychosomatic Research, 2011, 71, 97-101.	1.2	11
85	Hypertension in Russia: Changes Observed After 4 Years of a Comprehensive Health System Improvement Program in the Yaroslavl Region. Journal of Clinical Hypertension, 2017, 19, 198-204.	1.0	11
86	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1824-1832.	2.2	11
87	Resistant hypertension. Canadian Journal of Cardiology, 2009, 25, 315-317.	0.8	10
88	Developing consensus measures for global programs: lessons from the Global Alliance for Chronic Diseases Hypertension research program. Globalization and Health, 2017, 13, 17.	2.4	10
89	Comparison of Readmission and Death Among Patients With Cardiac Disease in Northern vs Southern Ontario. Canadian Journal of Cardiology, 2019, 35, 341-351.	0.8	10
90	Interâ€individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 561-568.	2.2	10

#	Article	IF	CITATIONS
91	Endothelin Receptor Antagonists: New Hope for Renal Protection?. Current Hypertension Reports, 2015, 17, 57.	1.5	9
92	The Cardiovascular Health in Ambulatory Care Research Team performance indicators for the primary prevention of cardiovascular disease: a modified Delphi panel study. CMAJ Open, 2017, 5, E315-E321.	1.1	9
93	Heart and Stroke Foundation of Ontario (HSFO) high blood pressure strategy's hypertension management initiative study protocol. BMC Health Services Research, 2008, 8, 251.	0.9	8
94	Hypertension Management Initiative: Qualitative Results From Implementing Clinical Practice Guidelines in Primary Care Through a Facilitated Practice Program. Canadian Journal of Cardiology, 2013, 29, 632-635.	0.8	8
95	Randomized Controlled Trial Comparing Automated Office Blood Pressure Readings After Zero or Five Minutes of Rest. Hypertension, 2021, 78, 353-359.	1.3	8
96	Enhancing Indigenous health research capacity in northern Ontario through distributed community engaged medical education at NOSM: A qualitative evaluation of the community engagement through research pilot program. Canadian Medical Education Journal, 2018, 9, e21-32.	0.3	8
97	The use of calcium antagonists in the treatment of hypertensive persons with kidney disease. Current Hypertension Reports, 2002, 4, 191-194.	1.5	7
98	Update on calcium antagonists and the kidney. Current Opinion in Nephrology and Hypertension, 2003, 12, 309-315.	1.0	7
99	Bioavailability of oral curcumin. Cmaj, 2019, 191, E428-E428.	0.9	7
100	The Malawi NCD BRITE Consortium: Building Research Capacity, Implementation, and Translation Expertise for Noncommunicable Diseases. Global Heart, 2020, 14, 149.	0.9	7
101	Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. Current Hypertension Reports, 2009, 11, 345-353.	1.5	6
102	Blood pressure 2 years after a chronic disease management intervention study. International Journal of Circumpolar Health, 2010, 69, 50-60.	0.5	6
103	Î <sup>2</sup> -Adrenergic Receptor Blockers in Hypertension. Canadian Journal of Cardiology, 2014, 30, S1-S2.	0.8	6
104	<p>Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study</p> . International Journal of Nephrology and Renovascular Disease, 2019, Volume 12, 49-58.	0.8	5
105	Risk of anyÂhypoglycaemia with newer antihyperglycaemic agents in patients withÂtype 2 diabetes: A systematic review and metaâ€analysis. Endocrinology, Diabetes and Metabolism, 2020, 3, e00100.	1.0	5
106	Individual Atrasentan Exposure is Associated With Longâ€term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacology and Therapeutics, 2021, 109, 1631-1638.	2.3	5
107	Change of education strategy associated with slippage in Canadian hypertension awareness treatment and control rates. Journal of Human Hypertension, 2021, 35, 1054-1056.	1.0	5
108	Management of hypertension: Regional variations in a greatly improved landscape. Canadian Journal of Cardiology, 2010, 26, 415-416.	0.8	4

#	Article	IF	CITATIONS
109	Regional and physician specialty–associated variations in the medical management of atherosclerotic renal–artery stenosis. Journal of the American Society of Hypertension, 2015, 9, 443-452.	2.3	4
110	MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): A Review & Study Protocol. Current Hypertension Reports, 2015, 17, 533.	1.5	4
111	Comparison of exposure response relationship of atrasentan between <scp>N</scp> orth <scp>A</scp> merican and <scp>A</scp> sian populations. Diabetes, Obesity and Metabolism, 2017, 19, 545-552.	2.2	4
112	Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80 mmHg: What's the Evidence?. Canadian Journal of Diabetes, 2018, 42, 166-172.	0.4	3
113	A retrospective observational populationâ€based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m 2 in Ontario, Canada. Diabetes, Obesity and Metabolism, 2021, 23, 916-928.	2.2	3
114	Acute post-streptococcal glomerulonephritis in northwestern Ontario: A six-year retrospective study. Jammi, 2016, $1$ , $17-24$ .	0.3	2
115	Controversies in hypertension: is lower blood pressure always better?. Journal of the American Society of Hypertension, 2016, 10, 618-620.	2.3	2
116	How should BP be measured inÂthe office?. Journal of the American Society of Hypertension, 2016, 10, 189-190.	2.3	2
117	Strategic, Successful, and Sustained Synergy: The Global Alliance for Chronic Diseases Hypertension Program. Global Heart, 2020, 14, 391.	0.9	2
118	DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol. BMC Endocrine Disorders, 2009, 9, 13.	0.9	1
119	Should age determine hypertension management? Recommendations from current guidelines. Journal of the American Society of Hypertension, 2016, 10, 7-9.	2.3	1
120	Age matters in the treatment and management of hypertension. Journal of the American Society of Hypertension, 2016, 10, 10-11.	2.3	1
121	Guideline Alignment in Related Areas. Canadian Journal of Cardiology, 2019, 35, 606-610.	0.8	1
122	The Rise and Fall of Hypertension Control in Canada: The Beginning of the End or the End of the Beginning?. Canadian Journal of Cardiology, 2021, 37, 679-682.	0.8	1
123	Abstract 52: KDIGO (Kidney Disease: Improving Global Outcomes) Guideline Update On The Management Of Blood Pressure In Chronic Kidney Disease: What's New And What's Different From Other Guidelines. Hypertension, 2021, 78, .	1.3	1
124	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. Hepatology, 1993, 18, 519-528.	3.6	1
125	Diabetes prevalence and demographics in 25 First Nations communities in northwest Ontario (2014–2017). Canadian Journal of Rural Medicine: the Official Journal of the Society of Rural Physicians of Canada = Journal Canadien De La Médecine Rurale: Le Journal Officiel De La Soci&:#x00e9:t&:#x00e9: De M&:#x00e9:decine Rurale Du Canada, 2020, 25, 139.	0.2	1
126	Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program. Open Medicine, 2012, 6, e127-33.	1.5	1

#	Article	IF	CITATIONS
127	Enhancing Indigenous health research capacity in northern Ontario through distributed community engaged medical education at NOSM: A qualitative evaluation of the community engagement through research pilot program. Canadian Medical Education Journal, 2018, 9, e21-e32.	0.3	1
128	Quantitating Dialysis in the Home Hemodialysis Patient: A Simple and Practical Approach. Home Hemodialysis International International Symposium on Daily Home Hemodialysis, 1998, 2, 34-37.	0.8	0
129	Applying the 2005 Canadian Hypertension Education Program recommendations: 5. Therapy for patients with hypertension and diabetes mellitus. Cmaj, 2005, 173, 1154-1157.	0.9	O
130	Valve Replacement Surgery Complicated by Acute Renal Failure-Predictors of Early Mortality. Journal of Cardiac Surgery, 2006, 21, 144-145.	0.3	0
131	A strategy to improve hypertension control: The Canadian experience. CVD Prevention and Control, 2010, 5, 107-113.	0.7	0
132	Renal denervation for human hypertension: is there a future?. Journal of the American Society of Hypertension, 2016, 10, 390-392.	2.3	0
133	What Can Declining Kidney Function Tell Us About Heart Failure?. Canadian Journal of Cardiology, 2018, 34, 1261-1263.	0.8	0
134	Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes. Circulation, 2020, 142, 1246-1248.	1.6	0
135	Patient- and Physician-Level Factors Associated With Adherence to C-CHANGE Recommendations in Primary Care Settings in Ontario. CJC Open, 2020, 2, 563-576.	0.7	0
136	An Interprofessional Approach in Caring for a Patient on Maintenance Hemodialysis with COVID-19 in Toronto, Canada: An Educational Case Report. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812095747.	0.6	0
137	Hypertension revisited. Canadian Family Physician, 2012, 58, 634-6.	0.1	0